WebDoctor Encyclopedia

Breast Invasive carcinoma Special types

Adenoid cystic carcinoma of the breast

Adenoid cystic carcinoma of the breast is a rare special type of breast cancer. Although it is usually triple-negative, the classic form grows slowly, seldom reaches the lymph nodes and carries an excellent outlook after surgery.

Medically reviewed Last reviewed October 20, 2026

What is adenoid cystic carcinoma of the breast?

Adenoid cystic carcinoma of the breast (ACCB) is a very rare type of breast cancer, making up well under 1% of breast cancers. It is better known as a cancer of the salivary glands, but the same type of tumour can also develop in the breast. Under the microscope, its cells form a pattern of small round spaces that looks like Swiss cheese, described as cribriform.

ACCB is unusual because of its receptor status. Most cases are triple-negative: they do not have oestrogen or progesterone receptors and do not overproduce HER2. In ordinary breast cancers, triple-negative disease tends to be aggressive. Classic ACCB is the opposite: it usually grows slowly, rarely spreads to lymph nodes and has an excellent outlook (Neilson et al., 2025).

Many adenoid cystic carcinomas carry a typical gene change, the MYB::NFIB fusion, or other alterations that switch on the MYB gene. This feature is shared with salivary gland adenoid cystic carcinoma and helps confirm the diagnosis.

Because ACCB behaves gently, experts increasingly favour less aggressive treatment. Surgery is the mainstay, and radiotherapy is often recommended after breast-conserving surgery. Chemotherapy rarely seems to help (Li et al., 2022). A small number of tumours, especially the solid-basaloid form, behave more aggressively and may need fuller treatment.

1. Key facts at a glance

Feature Details
Type of cancer Rare special type of invasive breast carcinoma
How common Well under 1% of breast cancers
Typical age Usually 50s-60s; median 61 in one large analysis
Receptor status Usually triple-negative (ER, PR and HER2 negative)
Genetic hallmark MYB::NFIB fusion or other MYB activation
Lymph node spread Uncommon
Main treatment Surgery, often with radiotherapy
Chemotherapy Rarely beneficial for classic tumours
Outlook Generally excellent

2. Types

Type Description Behaviour
Classic ACCB Cribriform, tubular and trabecular patterns with two cell types Favourable
Solid-basaloid ACCB Sheets of basaloid cells with fewer gland-like spaces More aggressive; higher risk of spread
ACCB with high-grade transformation Areas of high-grade carcinoma within the tumour Aggressive

How ACCB differs from typical triple-negative breast cancer

Feature Classic ACCB Typical triple-negative breast cancer
Growth rate Slow Often fast
Lymph node spread Rare More common
Distant spread Uncommon; can occur late, often to lungs More common, often early
Benefit from chemotherapy Not shown Substantial
Outlook Excellent More guarded

Adenoid cystic carcinoma of the breast and salivary glands

Feature Breast Salivary gland
Gene change MYB::NFIB common MYB::NFIB common
Spread along nerves Uncommon Common
Lymph node spread Rare Variable
Outlook Usually better Often slow but persistent disease

3. Causes and risk factors

The cause of ACCB is not known.

Factor Notes
Female sex Almost all patients are women; male cases are very rare
Age Mostly affects women after 50
Gene fusion in tumour cells Acquired; not inherited
Family history and BRCA No clear link established
General breast cancer risk factors Their role in ACCB is uncertain

4. How does it look

On imaging

A multi-centre imaging study showed that ACCB can look benign on scans (Guldogan et al., 2023).

Test Typical findings
Mammogram Round or oval mass, sometimes with well-defined margins
Ultrasound Oval mass parallel to the skin; may look grey-white or even cyst-like
MRI Bright on T2 images, restricted diffusion, often even enhancement
Doppler ultrasound Often no blood flow seen

In that study, combining the features from all imaging tests correctly placed every lesion in a suspicious category. However, most were only mildly suspicious (BI-RADS 4A), showing how easily these tumours can be underestimated.

Under the microscope

Feature Description
Pattern Cribriform, tubular, trabecular or solid
Two cell types Duct-lining (epithelial) cells and outer basal/myoepithelial cells
Spaces True glandular spaces and pseudo-spaces filled with basement membrane material
Stains CD117 (KIT) often positive; MYB positive
Grade Classic forms are usually low grade

Why the diagnosis can be difficult

ACCB is rare, so many pathologists see only a few cases in their career. On a small needle biopsy, it can be confused with benign conditions such as collagenous spherulosis, or with other cancers such as invasive cribriform carcinoma, which is hormone receptor-positive and treated differently. For this reason, the biopsy or the removed tumour is often sent for a second opinion from a specialist breast pathologist.

Special stains help. The presence of two cell types, staining for CD117 and MYB, and in some cases a test for the MYB::NFIB fusion, all support the diagnosis. Getting the diagnosis right matters, because it can spare people from treatments they do not need.

5. Symptoms

Common symptoms

  • A firm, painless or tender lump in the breast
  • A lump often lying under or near the nipple area
  • No symptoms, with the lesion found on a mammogram

Less common symptoms

Symptom Notes
Breast pain or tenderness More common than in other breast cancers
Skin changes Rare
Nipple discharge Rare
Lump in the armpit Uncommon, as nodal spread is rare
Cough or breathlessness Rare; may indicate lung spread

When to seek medical advice

See a doctor if you notice a new breast lump or other breast change. Attend routine screening when invited.

6. Diagnosis

Test Purpose
Clinical breast examination Assesses the lump and the armpit
Mammogram and ultrasound Main imaging tests
Core needle biopsy Confirms cancer and type
Receptor and HER2 tests Usually negative
MYB staining or gene testing Supports the diagnosis
Specialist pathology review Separates ACCB from look-alikes such as cribriform carcinoma or collagenous spherulosis
MRI Selected cases, for example to assess extent
CT scans For larger, solid-basaloid or high-grade tumours

Staging uses the standard breast cancer TNM system. In a large SEER-based study, almost all patients (99.5%) were diagnosed at stage I or II (Li et al., 2022).

7. Treatment

There are no randomised trials in ACCB. Treatment advice comes from population databases, case series and expert reviews (Neilson et al., 2025).

Surgery

Option Notes
Breast-conserving surgery Suitable for most tumours
Mastectomy For larger tumours or patient preference
Clear margins Important, as local recurrence can occur
Sentinel lymph node biopsy Commonly done, although nodal spread is rare; omission is increasingly discussed

Radiotherapy

Situation Approach
After breast-conserving surgery Usually recommended
After mastectomy Considered for large tumours, close margins or node involvement

An analysis of 488 SEER patients found better overall survival in those who had radiotherapy after surgery (Gomez-Seoane et al., 2021). The authors recommended considering radiotherapy, especially for patients with risk factors such as nodal spread or high grade.

Chemotherapy

A study of 661 patients from American and Chinese databases found that chemotherapy after surgery did not improve overall or breast cancer-specific survival, even in higher-risk subgroups (Li et al., 2022). Only about one in eight patients had received it.

Situation Chemotherapy role
Classic, early-stage ACCB Usually not recommended
Solid-basaloid or high-grade ACCB May be discussed
Spread to distant organs Considered case by case

Hormone and targeted therapy

Treatment Notes
Hormone therapy Rarely useful, as most tumours lack hormone receptors
Targeted drugs Under study, for example agents acting on MYB-related pathways
Clinical trials Recommended for advanced disease

Summary of current approach

Recent reviews support radiotherapy after surgery, with the option of omitting axillary staging and systemic therapy for many patients (Neilson et al., 2025). Each plan is individual and should be discussed by a breast multidisciplinary team.

Understanding your pathology report

Term Meaning
ER and PR negative The tumour does not respond to hormones
HER2 negative HER2-targeted drugs will not help
Triple-negative All three of the above are negative
Grade How abnormal the cells look; classic ACCB is usually low grade
Margins Whether healthy tissue surrounds the removed tumour
Solid component The proportion of solid-basaloid tumour, which affects risk

Recovery and treatment timeline

Stage What to expect
Surgery Usually a day case or one night in hospital
First 2 weeks Wound healing and gentle arm exercises
2-3 weeks after surgery Full pathology results and treatment plan
4-8 weeks after surgery Radiotherapy begins, if recommended
Radiotherapy course Usually 1-3 weeks of weekday sessions

Many people are back to most normal activities within a few weeks of finishing treatment, although tiredness can last longer.

Side effects

Treatment Possible side effects
Surgery Pain, bruising, change in breast shape, fluid collection
Sentinel node biopsy Small risk of arm swelling and numbness
Radiotherapy Skin redness, tiredness, breast firmness or swelling
Chemotherapy, if used Tiredness, infection risk, hair loss, nausea

8. Outlook (prognosis)

Factor Effect
Classic type Excellent outlook
Solid-basaloid type Higher risk of recurrence and spread
Lymph node involvement Linked with poorer survival
Higher grade or stage Linked with poorer breast cancer-specific survival
No radiotherapy Linked with poorer survival in database studies

In the Li et al. (2022) analysis, lymph node spread, higher stage, grade 2 or above and not receiving radiotherapy were linked with worse breast cancer-specific survival.

Distant spread, when it happens, may appear many years after diagnosis, often in the lungs. Long-term follow-up is therefore advisable.

9. Follow-up

Follow-up Typical schedule
Clinic review Every 6-12 months for at least 5 years
Mammogram Yearly
Chest imaging If symptoms develop or for higher-risk types
Long-term awareness Report new lumps, cough or breathlessness, even years later

10. Living with adenoid cystic carcinoma of the breast

  • Ask whether your tumour is classic or solid-basaloid, as this affects treatment
  • Do not assume triple-negative means aggressive in your case; discuss it with your team
  • Keep active and maintain a healthy weight
  • Check your breasts and report changes
  • Look after your skin during radiotherapy with gentle, unperfumed products
  • Wear a soft, supportive bra while the wound heals and during radiotherapy
  • Seek support from breast cancer and rare cancer charities

Living well after treatment

Most people with classic ACCB can expect to return to their usual lives. Regular exercise, a balanced diet and limiting alcohol support general health and recovery. Some people feel anxious because their diagnosis is so rare and information is limited; specialist breast care nurses and support groups can help with these concerns.

11. Frequently asked questions

Question Answer
Is it the same as triple-negative breast cancer? It is triple-negative, but usually much less aggressive
Will I need chemotherapy? Usually not for classic, early-stage tumours
Will I need radiotherapy? It is often recommended after breast-conserving surgery
Do my lymph nodes need checking? Often a sentinel node biopsy is done, but this may be omitted in some cases
Can it come back? Yes, though uncommonly; late lung spread is possible
Is it inherited? No clear inherited link is known
Will I need hormone tablets? Usually not, because the tumour lacks hormone receptors
Can men get it? Very rarely
Why was I told my cancer is triple-negative but low risk? ACCB is an exception to the usual rule; its biology is different from typical triple-negative cancer
Should I have genetic testing? Ask your team; it depends on your personal and family history rather than the tumour type

12. Questions to ask your care team

  • Is my tumour classic or solid-basaloid?
  • What grade and stage is it?
  • Do I need sentinel lymph node biopsy?
  • Do you recommend radiotherapy, and why?
  • Is there any benefit from chemotherapy in my case?
  • What follow-up will I need, and for how long?
  • Has my biopsy been reviewed by a specialist breast pathologist?
  • Who can I contact if I notice new symptoms?

Resources

  1. Gomez-Seoane, A., Davis, A. and Oyasiji, T. (2021) ‘Treatment of adenoid cystic carcinoma of the breast: is postoperative radiation getting its due credit?’, The Breast, 59, pp. 358-366.
  2. Guldogan, N. et al. (2023) ‘Adenoid cystic carcinoma of the breast: multimodality imaging findings and review of the literature’, Academic Radiology, 30(6), pp. 1107-1117.
  3. Li, L., Zhang, D. and Ma, F. (2022) ‘Adenoid cystic carcinoma of the breast may be exempt from adjuvant chemotherapy’, Journal of Clinical Medicine, 11(15), 4477.
  4. Neilson, T. et al. (2025) ‘Adenoid cystic carcinoma of the breast: a narrative review and update on management’, Cancers, 17(7), 1079.
  5. National Cancer Institute (2026) Breast Cancer Treatment (PDQ) – Health Professional Version. Available at: https://www.cancer.gov/types/breast/hp/breast-treatment-pdq (Accessed: October 2026).

Prepared by the editorial team, October 2026.